EVAX (Evaxion AS) GF Value Rank: 10 (As of Sep. 03, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EVAX Evaxion AS EVAX
50 GF Score
Price $3.07
GF Value $3.34
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Evaxion AS GF Value Rank?

Evaxion AS EVAX -0.81% 50 GF Value Rank is 10 as of Sep. 03, 2026, which is at its 10-year median of 10.00. GuruFocus rates EVAX with a GF Score™ of 50/100 and a GF Value™ of $3.34 (Fairly Valued). The stock has 1 warning sign investors should review.

Evaxion AS has the GF Value Rank of 10.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

EVAX vs DYAI, ATOS, PVCT: GF Value Rank Comparison

For the Biotechnology subindustry, Evaxion AS's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evaxion AS GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion AS's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Evaxion AS's GF Value Rank falls into.


EVAX
50GF Score
Evaxion AS EVAX
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 10 mean?
Evaxion AS (EVAX) has a GF Value Rank of 10 as of Sep. 03, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Evaxion AS and its competitors. This is near median its historical median of 10.00. Over the past decade, Evaxion AS's GF Value Rank has ranged from 10.00 to 10.00.
Is Evaxion AS's GF Value Rank too high?
Evaxion AS's current GF Value Rank of 10 is near median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 10.00. Overall, Evaxion AS has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's GF Value Rank compare to DYAI and ATOS?
Evaxion AS's GF Value Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Evaxion AS's own GF Value Rank has ranged from 10.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Evaxion AS and its competitors. Evaxion AS's current GF Value Rank is 10, which is near median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Based on GuruFocus' analysis, Evaxion AS (EVAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.34, compared to a current price of $3.07 — trading 8.1% below its estimated fair value. The current GF Value Rank is 10, which is near median its 10-year median of 10.00. Evaxion AS's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Evaxion AS (EVAX), the current GF Value Rank is 10 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evaxion AS (EVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Evaxion AS stock appears to be undervalued. The current stock price of $3.07 is trading 8.1% below its estimated GF Value™ of $3.34. GuruFocus considers Evaxion AS to be Fairly Valued.

Key valuation signals for EVAX:

  • GF Value Rank: 10 (near median its 10-year median of 10.00)
  • GF Value™: $3.34 vs. price of $3.07 (8.1% below fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the EVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evaxion AS Business Description

Address Dr. Neergaards Vej 5f, Horsholm, DNK, 2970
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
50GF Score

Get the complete analysis for EVAX

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.07
Price
$3.34
GF Value